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ABSTRACT  
 
Purpose of review:  
Mycoplasma hominis and Ureaplasma urealyticum may colonize the human genital tract and 
have been associated with adverse pregnancy outcomes. Chorioamnionitis, spontaneous preterm 
labour and preterm premature rupture of membranes are significant contributors to neonatal 
morbidity and mortality. However, since these bacteria can reside in the normal vaginal flora, 
there are controversies regarding their true role during pregnancy and thus the need to treat these 
organisms. 
 
Recent findings:  
We review here the recent data concerning mycoplasmas epidemiology and their clinical role 
during pregnancy. The association of these organisms with preterm labour has been suggested by 
many observational studies, but proof of causality remains limited. Polymerase chain reaction is 
an excellent alternative to culture to detect the presence of these organisms, but culture allows 
antibiotic susceptibility testing. Whether antimicrobial treatment of mycoplasma-colonised 
pregnant patients can effectively reduce the incidence of adverse pregnancy outcomes warrants 
further investigations.  
 
Summary:  
The role of Mycoplasma spp. and Ureaplasma urealyticum in adverse pregnancy outcomes is 
increasingly accepted. However, sole presence of these microorganisms in the vaginal flora 
 
 
might be insufficient to cause pathological issues, but their combination with other factors such 
as bacterial vaginosis or cervical incompetence are needed to induce preterm birth.  
 
 
Keywords:  
Mycoplasma Ureaplasma, neonatal infections, chorioamnionitis, preterm premature rupture of 
fetal membranes (PPROM), prematurity 
 
 
 
 
 
 
INTRODUCTION 
Adverse pregnancy outcomes that include miscarriage, stillbirth and preterm labour are a major 
clinical concern for obstetricians and neonatologists. Miscarriage and stillbirth are defined as the 
spontaneous termination of pregnancy before and after 20 weeks of gestation respectively [1]. 
Chorioamnionitis is an acute infection of the placental membranes, and includes both the clinical 
intrauterine infection and/or the histological processes [2]. Preterm labor (PTL) occurs before 37 
weeks gestation and is defined as uterine contractions that lead to shortening of the cervix. All 
these conditions could be occasionally caused by genital mycoplasma. 
Over 200 different species of Mycoplasma and Ureaplasma have been identified to date in 
animals, arthropods and plants [3, 4]. In humans, these species are now known to be located 
primarily in the respiratory or urogenital tracts. Mycoplasma was first isolated from a Bartholin's 
gland abscess in 1937[5]. However, the term Mycoplasma was only introduced in the 1950’s and 
it originates from the Greek "fungus" (mykes) and "formed" (plasma). Ureaplasma was cultured 
in vitro for the first time in 1954, after being isolated from urethras of men presenting with 
nongonococcal urethritis [6]. In the 1960’s, these organisms were found to be unable to produce 
peptidoglycans and cell wall components, making them unique among the prokaryotes. Lacking 
a rigid cell wall make Mycoplasma osmotically fragile, resistant to β-lactam antibiotics and 
prevents Gram staining. Due to their small genomes and their limited biosynthetic abilities, these 
fastidious microorganisms require complex growth media (with sterol and serum), which limited 
our understanding of their ecology and pathogenesis. However, during the last ten years, new 
molecular methods have significantly increased our understanding of their epidemiology and 
pathogenic potential. 
 
 
Historically, Mycoplasma hominis and Ureaplasma urealyticum have been the subject of many 
studies, especially on their role in infections of the genital tract. A growing body of evidence 
suggest an association of Mycoplasma and Ureaplasma with adverse pregnancy outcomes, 
including infertility, miscarriage, stillbirth, PTL, postpartum endometritis, as well as 
chorioamnionitis. Moreover, neonates might develop Mycoplasma and Ureaplasma related lung 
diseases, bacteremia and meningitis. On the other hand, these bacteria can also be part of the 
normal genital flora, which raised controversies concerning their role in adverse pregnancy 
outcomes.  
In the present paper, we aim to review recent data that link these 2 microorganisms with the 
above mentioned adverse pregnancy outcomes. This review should benefit both infectious 
disease specialists and obstetricians in the understanding of pathological outcomes related to 
mycoplasma during pregnancy. Neonatal infections, Mycoplasma-related ectopic pregnancies or 
post-partum endometritis are reviewed elsewhere [3, 4, 7-9]. 
 
 
 
 
EPIDEMIOLOGY  
Ureaplasma urealyticum and Mycoplasma hominis are often identified simultaneously in 
women’s the vulvovaginal flora [10, 11], therefore, the term "genital mycoplasmas" is often used 
in the literature to refer to both species. Genital mycoplasmas can be detected in 67%, 40%, and 
25% of sexually active, sexually inactive and postmenopausal women, respectively [12]. 
Colonization during pregnancy with U. urealyticum and M. hominis varies between 35-90% and 
5-75%, respectively [13, 14]. The prevalence of these microorganisms has been significantly 
associated with low socioeconomic status, ethnicity, hormonal changes (pregnancy, menopause) 
and high number of sexual partners. [4, 10, 15]. Consequently, when studying the prevalence of 
these bacteria in women, all these co-variables or confounding factors should be considered, 
since they largely explain the variation in prevalence between different studies (Table 1A&B). 
 
UREAPLASMA, MYCOPLASMA & ADVERSE PREGNANCY OUTCOMES  
A direct causal relationship between U. urealyticum and M. hominis and adverse pregnancy 
outcomes is difficult to demonstrate, due to the polymicrobial colonization of the genital tract 
and high prevalence of colonization. The precise significance of U. urealyticum and M. hominis 
in bacterial vaginosis thus remains debatable [3, 16, 17].  
Growing experimental evidence of adverse pregnancy outcomes has been accumulated using 
different animal models (reviewed in [16]). Moreover, Mycoplasma are the most common 
microorganisms isolated from amniotic fluid, cord blood, respiratory tract and cerebrospinal 
fluid of infants born prematurely who develop bronchopulmonary dysplasia and developmental 
disabilities [12, 16]. 
 
 
Table 1A summarizes human studies examining Ureaplasma in pregnancy and their relationship 
with adverse pregnancy outcomes (including PTL, premature preterm rupture of membranes 
[PPROM] and chorioamnionitis). In uncomplicated pregnancies (“Controls” in Table 1A), 
colonization with U. urealyticum ranged from 2.7% to 70%. Huge variations in colonization 
rates with this organism were observed between studies. Conflicting results in the literature may 
be attributed to the following factors: 1) study design (prospective or retrospective); 2) 
gestational age at study entry (1
st
 or 2
nd
 trimester or at symptoms occurrence); 3) outcome 
studied (preterm labor with or without preterm birth); 4) site of sample collection (vagina, 
amniotic fluid or placenta); 5) diagnostic method used (culture and/or PCR; specificity of the test 
at species level); 6) target other pathogens (bacterial vaginosis). Among 22 studies comparing 
adverse pregnancy outcomes with a control group of uneventful pregnancies, 15 showed a 
significant association with the presence of U. urealyticum (Table 1A). Most of these studies 
were based on cervico-vaginal samples (n=17/22) and culture methods (n=16/22). A significant 
association between Ureaplasma and adverse pregnancy outcomes was found more frequently 
when culture was used (n=12/16) rather than PCR (n=3/6), which may reflect publication bias. 
Among the 5 studies based on amniotic fluid samples, all but one small study (n=40) [18] 
demonstrate a significant association between Ureaplasma and adverse pregnancy outcomes. 
Regarding Mycoplasma hominis, a significant association with adverse pregnancy outcome was 
found in 6 out of 11 studies (Table 1B). Most of these studies were based on cervico-vaginal 
samples (n=8). It is noteworthy that all the studies based on amniotic fluid samples showed a 
significant association between M. hominis and adverse pregnancy outcomes. 
Studies published during the last 3 years add significant support to the role of urogenital 
mycoplasmas in adverse pregnancy outcome. Choi et al. [11] detected U. urealyticum and M. 
 
 
hominis in 62.7% and 12.7% of pregnant patients with symptoms of PTL, respectively. Despite a 
higher observed prevalence in the subgroup of patients who ultimately delivered preterm, 
statistical significance was not reached. 
A recent large prospective observational study [19] of cervical swabs obtained at the first 
prenatal visit found a significant correlation between preterm delivery and Ureaplasma 
colonization (odds ratio (OR) 1.64; 95% confidence interval (CI) 1.08-2.48; p = 0.02). The 
authors used multiple logistic regression analysis to control for known risk factors for preterm 
birth and the presence of other pathogenic microorganisms. 
Bayraktar et al. [10] found that 54% of patients were positive for U. urealyticum and/or M. 
hominis in the symptomatic group, whereas only 4% were positive for these organisms in the 
control group (p<0.05). The presence of these bacteria was also significantly correlated with low 
birth weight and early gestational age. However, the low prevalence of mycoplasma in the 
uneventful pregnancy group may reflect a bias in the number of sexual partners and exposure to 
other pathogens.  
Kacerovsky et al. [20, 21] recently published 2 reports investigating the presence of mycoplasma 
in amniotic fluids of pregnancies complicated by PPROM. Chorioamnionitis was associated with 
a higher bacterial load of genital mycoplasmas [20]. Moreover, the intensity of the intra-amniotic 
inflammatory response to genital mycoplasmas was inversely related to gestational age [21]. 
This may explain the increased rate of adverse pregnancy outcomes and vertical transmission of 
mycoplasmas in very preterm or low birth weight neonates [22, 23]. In addition, intraamniotic 
and maternal inflammatory responses were more severe with mycoplasma than with other 
microorganisms in patients with PPROM [24]. Finally, Ureaplasma was isolated from 63 out of 
151 placentas from preterm delivered infants (<32 weeks of gestation) [25]. Evidence of 
 
 
chorioamnionitis was identified in 83% of the Ureaplasma-positive placentas and only in 30% of 
the Ureaplasma-negative ones (p<0.01). Ureaplasma-colonization was therefore an independent 
risk factor for chorioamnionitis (OR 11; 95%CI 5-25) [25]. 
 
 
 
DIAGNOSIS 
Advantages and limitations of serology, culture and molecular methods for the diagnosis of 
mycoplasma infections have recently been reviewed by Waites et al. [26]. Here, we focus on 
diagnostic methods of Ureaplasma urealyticum and Mycoplasma hominis during pregnancy. 
  
Serology  
To our knowledge, there are no serological assays for genital mycoplasma that have been 
standardized and made commercially available. Thus, serological tests have been primarily 
developed and used in research settings.  
 
Culture  
The gold standard for detection of Mycoplasma hominis and Ureaplasma spp. remains culture. 
These bacteria may be isolated from vaginal secretions, amniotic fluid, placental tissue and cord 
blood during pregnancy. Culture has a major advantage in that it provides isolates for 
antimicrobial susceptibility testing. Appropriate techniques and media are needed to perform 
cultures of these organisms (Figure 1). Several limitations to the broad use of culture include 
susceptibility to drying, need for specific expensive media, 2-5 days laboratory procedures and 
technical expertise. Moreover, definitive species identification may require additional 
investigations such as PCR assay [4, 26], also some commercial growth media allow 
differentiation between U. urealyticum and M. hominis (Figure 1c).  
 
PCR 
 
 
Several PCR diagnostic protocols for detection of M. hominis and U. urealyticum are available, 
which target urease, 16S rRNA or the multiple-banded antigen (mab) gene [26-28]. Moreover, 
species and serovar-specific primers are available [26-28]. PCR has several advantages when 
compared to other diagnostic tools: (1) no viable organisms are needed (positivity even after 
antibiotic treatment), (2) the limit of detection is lower than in culture, and (3) results are 
available in less than 24 hours. Table 3 shows the detection rate of culture and PCR methods in 
studies performed during pregnancy. All but one study [11] show better sensitivity with PCR 
compared to culture [29, 76, 77].  Oh et al. found that culture of amniotic fluid alone would have 
missed 91% of genital Mycoplasma [29]. 
Conventional PCR, real-time PCR (for detection and quantification), nested-PCR (re-
amplification with a second set of primers) and multiplex PCR have all been used for genital 
mycoplasma detection. In year 2010, Xiao et al. [27] compared culture with conventional PCR 
and a new species-specific multiplex real-time PCR. Real time PCR detected 15.2% more 
positive samples than did culture (24.2% versus 39.4%). Among Ureaplasma-positive cultures, 
multiplex real-time PCR assay reduced false-negative results from 9.3% to 3.1% compared to 
traditional PCR.  
Others have also developed tools for the simultaneous detection of multiple genital pathogens, 
such as Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Mycoplasmas, 
Treponema pallidum, and herpes simplex virus type 1 and 2 in urogenital specimens[30, 31]. 
Finally, novel rapid DNA microarray assays enable identification of up to 37 Mycoplasma 
species from single and multiple infections in a single run [32]. 
 
 
 
 
TREATMENT DURING PREGNANCY  
Antimicrobial susceptibility of Ureaplasma and Mycoplasma 
Antimicrobial susceptibility of Ureaplasma and Mycoplasma isolated during pregnancy are 
shown in table 2, where data were compiled from the recent studies [4, 10, 11, 33, 34]. Since 
Mycoplasma and Ureaplasma lack peptidoglycan, they are naturally resistant to beta-lactams. 
Sulfonamides or trimethoprim are also inefficient against these bacteria due to the absence of 
folic acid synthesis. Mycoplasma spp. are generally considered susceptible to tetracyclines, 
fluroquinolones, macrolides and clindamycin; about 10% and 40% of Ureaplasma and 
Mycoplasma spp. are resistant to tetracyclins, with potential cross-resistance to erythromycin. As 
proposed by others [3, 35], clindamycin may represent a potential safe treatment during 
pregnancy for Ureaplasma and Mycoplasma spp. resistant to macrolides, since tetracyclines are 
contraindicated.  
In recent studies investigating strains isolated during pregnancy [10, 11], antimicrobial 
susceptibility of U. urealyticum was different from that of M. hominis: U. urealyticum was more 
sensitive to macrolides whereas M. hominis was more sensitive to quinolones, congruent with 
known MCI (table 2 ) 90. 
Only few studies investigated maternal and transplacental pharmacokinetics of different 
antibiotics [36, 37]. Azithromycin has a rapid serum half-life in gravid women with a prolonged 
half-life and high-sustained antibiotic levels noted within myometrium and placental tissue. 
However, Heikkinen et al.[37] reported that the transfer of erythromycin and azithromycin 
across the human placenta were only 3.0% and 2.6%, respectively. Some authors reinforce the 
urgent need to study maternal and transplacental pharmacokinetics and placental transfer 
antibiotic regimens efficient on mycoplama [16]. Based on clinical studies, azythromycin 
 
 
appears to be an excellent treatment for both genital mycoplasma. Indeed, similar U. urealyticum 
eradication rates (>90%) were obtained with azythromycin 1g single dose versus doxycycline for 
7 days [89].  
 
  
Antimicrobials to prevent adverse pregnancy outcomes in patients colonized with 
Ureaplasma and Mycoplasma 
It is difficult to make specific recommendations for genital mycoplasma infections treatment in 
pregnant women, because very few clinical studies address in vivo efficacy of antibiotics. 
Experimental animal model studies showed that specific maternal antibiotic therapy can 
eradicate Ureaplasma from amniotic fluid, placenta and fetus, with subsequent prolongation of 
pregnancy and less severe neonatal injuries [38]. 
Although there are reports of maternally administered antibiotics for eradication of mycoplasma 
intra-amniotic infection, there is little agreement in the literature regarding their effectiveness in 
preventing adverse pregnancy and neonatal outcomes [34, 39-43].  
In one study [42], second trimester amniocentesis samples were cultured for U. urealyticum, and 
positive cultures were found in 44 out of 2,718 cases (1.6%). Thirty-five culture-positive patients 
were treated with oral erythromycin. The rates of second trimester spontaneous abortion was 
11.4% and 44.4% in treated and untreated patients, respectively, while the rate of preterm 
delivery was similar between the two groups (19.4 and 20%). This work suggest the 
effectiveness of erythromycin on U. urealyticum fetal infection. However, other pathologic 
agents related to miscarriage, such as Waddlia chondrophila [44-47] not tested in this work and 
susceptible to erythromycin[48] may act as confounding factors. Other case reports gave similar 
 
 
results: Romero et al. [39] and Mazor et al. [41] both reported that U. urealyticum was 
eradicated from the amniotic fluid of 2 patients after a course of antibiotic treatment which 
included erythromycin for 6-10 days. 
In 2011, the Cochrane database identified only one eligible randomized control trial investigating 
antibiotic use in pregnant women colonized with either U. urealyticum or M. hominis[49]. In this 
study, colonized pregnant women were treated with erythromycin or clindamycin (n=644) versus 
placebo (n=427) between 22-32 weeks of gestation. There was no data to assess the effectiveness 
of antibiotics in reducing the incidence of premature birth. The rate of low birthweight (under 
2500g) was not statistically different between groups. Of note, over 50% of women were 
excluded from the analysis due to poor adherence to the study protocol.  
In conclusion, the indications for treatment, the choice of medication (or antibiotic), the dosage 
and the duration remain to be further studied and defined. Based on this review, we propose to 
treat U. urealyticum using macrolides as first-line treatment and clindamycin as second-line. For 
M. hominis that is generally resistant to macrolides, clindamycin represent the first choice given 
the relative contraindication of doxycicline and quinolones during pregnancy.  
 
 
 
 
 
 
CONCLUSION 
We reviewed here the literature regarding Mycoplasma and Ureaplasma with an emphasis on the 
last two years. Growing evidences suggest a role of these microorganisms in adverse pregnancy 
outcomes. For diagnosis, culture is still the gold standard, but molecular methods are useful 
complementary tools. The treatment during pregnancy is still debated, mainly concerning 
prevention of preterm labour. Analysis of the whole vaginal microbioma is needed to define the 
specific role of Mycoplasma and Ureaplasma in combination to the other microorganisms during 
pregnancy. Indeed, study of the vaginal microbiota and its natural dynamics in healthy pregnant 
women and women suffering from PTL may give new answers for the very limited 
understanding of the etiology of preterm birth. 
 
 
 
 
 
KEY POINTS 
 Prevalence of Mycoplasma hominis and Ureaplasma urealyticum during pregnancy 
depends on many factors: socioeconomic status, race, number of sexual partners, 
maternal and gestational ages, site of sampling and diagnostic method used, presence of 
other pathogens (such as BV) and adverse pregnancy outcomes. 
 The gold standard for identification of Mycoplasma hominis and Ureaplasma urealyticum 
is culture. PCR is more sensitive, less time consuming and allows differentiation between 
genera and species. 
 Growing evidences from clinical and experimental studies suggests that both 
cervicovaginal colonisation and/or amniotic fluid infection induce an inflammatory 
response resulting in chorioamnionitis, preterm labor, preterm premature rupture of 
membranes, all leading to potential adverse neonatal outcomes such as 
bronchopulmonary dysplasia. 
 Clindamycin, erythromycin and azythromycin may prevent adverse pregnancy outcomes 
in patients colonized by Mycoplasma hominis and Ureaplasma urealyticum. 
 Additional studies using different antibiotics are now warranted to elucidate the role of 
mycoplasma in each different adverse pregnancy outcome and to compare the different 
antibiotic regimen in terms of pharmacodynamics and efficacy. 
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TABLES & FIGURE TITLES AND LEGENDS 
All tables and figures presented in this paper are "originals". None were "previously published". 
 
Figure 1: 
1A:  
For culture, samples should be inoculated in 10B broth under atmospheric conditions. Cultures 
are observed for up to 7 days for broth color change from yellow to pink, indicating pH change 
due to urease activity. Any broth with color change should be sub-cultured on A8 agar in 5% 
CO2 at 37°C. Colonies of Ureaplasma spp. (arrowhead) are identified by their characteristic 
brown appearance on A8 agar in the presence of the CaCl2 indicator. M. hominis (arrow) 
precipitate and show a typical ”fried-egg” aspect (low magnification).  
 
1B: 
Identification of M. hominis and U. uraelyticum using the Mycoplasma Duo kit (BioRAd, 
Nanterre, France). The kit must be read at 24 and 48 hours. Yellow and red media mean negative 
and positive cultures, respectively. 
Wells 2 & 5 = negative controls 
Wells 1 & 4 = U. Urealyticum 
Wells 3 & 6 = M. hominis 
Wells 4 & 6 = if positive, means >10
4
 colonies / ml. 
 
 
 
 
 
 
Table 1A & 1B: 
1A: studies investigating the role of U. Urealyticum alone in adverse pregnancy outcomes. 
1B: studies investigating the role of M. hominis alone or in combination with U. Urealyticum in 
adverse pregnancy outcomes. 
PCR = Polymerase Chain Reaction or molecular methods, V = Vaginal swab, PPROM = Preterm 
Premature Rupture of Membranes, AF = amniotic fluid, PTL = Preterm Labor, P = Placenta, 
Chorio = chorioamnionitis 
* Review of 12 published studies before 1989 [39]. 
** Review of 15 published studies before 1996 [14].  
 
Table 2:   
Antimicrobials susceptibilities to U. urealyticm and M. hominis isolates from samples obtained 
during pregnancy. Data were compiled from the following 5 studies:  
Waites et al., Clin Micro Reviews, 2005 4  
Bayraktar, Int J infect Dis, 2010 [10] 
Choi, Ann Lab Med, 2012 11]  
De Francesco - J Infect Chemother – 2012 33] 
Gomez, J Matern Fetal Neonatal, 2007 34] 
MIC = Minimum Inhibitory Concentration  
 
Table 3:  
 
 
Studies investigating both molecular and cultures diagnostic methods for identification of U. 
urealyticm and M. hominis during pregnancy. 
PCR = Polymerase Chain Reaction or molecular methods. 
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Published reports Number Diagnostic Specimen Condition Controls Study Statistical
of patients method  studied group significance
Ureaplasma urealyticum
Breugelmans M (19) 1988 Culture V PTL 41.4% 53.6% <0.05
Harada K (50) 145 Culture V PTL 30% 51.1% <0.05
Abele-Horn M (51) 295 Culture V PTL 51.8% 78.1% <0.001
Abele-Horn M (52) 253 Culture V PTL 57.1% 89.7 <0.001
Carey JC (43) 4934 Culture V PTL 65.6% 66.5% NS
Horowitz S (54) 362 Culture V PTL 42% 77% <0.001
Kafetzis DA (22) 251 Culture V PTL 38% 36.5% NS
Lamont RF (56) 88 Culture V PTL 46% 86% <0.01
Donders GG (58) 228 Culture V PTL 4.1% 23.8% <0.01
Kacerovský M (59) 450 Culture V PPROM 17% 68% <0.001
Rezeberga D (60) 151 Culture V Chorio 26.6% 45.7% NS
Horowitz S (54) 349 Culture V PPROM 42% 74% <0.001
Horowitz S (55) 389 Culture AF PPROM 2.9% 17.8% <0.01
Witt A (61) 207 Culture AF + P PPROM + PTL 2.7% 43.9% <0.001
Horowitz S (62) 214 Culture AF PTL 2.8% 20% <0.05
Choi SJ (11) 126 Culture V PTL 53.8% 60.9% NS
Mitsunari M (63) 82 PCR V PTL 45.8% 87% <0.001
Abele-Horn M (64) 198 PCR V Abortion 20% 42% <0.05
Kataoka S (65) 877 PCR V PTL 8.8% 4.8% NS
Govender S (66) 199 PCR V PTL 25% 25% NS
Gerber S (67) 254 PCR AF PTL 5.3% 63% <0.0001
Marconi C (18) 40 PCR AF PTL 0% 15% NS
Namba F (25) 151 Culture P Chorio + PTL - 42% -
Yoon BH (68) 120 Culture AF PPROM - 21% -
Yoon BH (69) 181 Culture AF PTL - 6.1% -
Ogasawara KK (43) 51 Culture V PPROM + PTL - 65% -
Gauthier DW (70) 225 Culture AF PPROM - 15% -
Olomu IN (71) 866 Culture P PTL - 6% -
Kirchner L (72) 49 Culture AF PPROM + PTL - 22% -
Ogasawara KK (73) 60 Culture V PPROM + PTL - 79.7% -
Kundsin RB (74) 647 Culture P PPROM + PTL - 28% -
McDonald (75) 122 Culture P Abortions - 17.2% -
Yoon BH (76) 257 Culture/PCR AF PTL - 7.1% -
Yoon BH (77) 154 Culture/PCR AF PPROM - 29.2% -
Jacobsson B (78) 197 PCR AF PPROM - 5.6% -
Kacerovsky M (21) 145 PCR AF PPROM - 24.1% -
Kacerovsky M (20) 103 PCR AF PPROM - 35.9% -
Bujold E(79) 55 PCR AF Cervix insuff - 9.1% -
Grattard F (80) 208 PCR V PPROM + PTL - 47.6% -
Jacobsson B (81) 58 PCR AF PPROM - 15.5% -
Jacobsson B (82) 61 PCR AF PTL - 3.3% -
Lee S. I. (83) 977 Culture V PTL 3.7%
Romero R* (13) 7133 Culture V Routine 70% (44-81%) - -
Carroll SG** (14) 24007 Culture V Routine 68% (35-90%) - -
Table 1A: 
 
 
 
 
 
 
 
 
Table
Published reports Number Diagnostic Specimen Condition Controls Study Statistical
of patients method  studied group significance
Mycoplasma hominis
Rezeberga D (60) 151 Culture V Chorio 4.8% 6.5% NS
Kacerovský M (59) 450 Culture V PPROM 15% 28% <0.001
Harada K (50) 145 Culture V PTL 6% 15.6% <0.05
Donders GG (57) 228 Culture V PTL 1.5% 19% <0.01
Lamont RF (56) 88 Culture V PTL 8% 24% NS
Choi SJ (11) 126 Culture/PCR V PTL 3.8% 17.3% NS
Kataoka S (65) 877 PCR V PTL 11% 19% NS
Marconi C (18) 40 PCR AF PTL 5% 35.5% <0.05
Nguyen DP (73) 456 PCR AF PTL 6.8% 33.3% <0.05
Govender S (66) 199 PCR V PTL 63% 55% NS
Nguyen DP (73) 456 PCR AF PTL 6.8% 33.3% <0.05
Kundsin RB (74) 647 Culture P PPROM + PTL - 6% -
McDonald H. (75) 122 Culture P Abortions - 2.5% -
Kacerovsky M (21) 145 PCR AF PPROM - 1.4% -
Kacerovsky M (20) 103 PCR AF PPROM - 2.9% -
Grattard F (80) 208 PCR V PPROM + PTL - 11% -
Lee S. I. (83) 977 Culture V PTL 28.6%
Romero R (13) 7133 Culture V PTL 27% (5-49%) - -
Carroll SG (14) 24007 Culture V Routine 27% (10-75%) - -
Ureaplasma urealyticum & Mycoplasma hominis
Bayraktar MR (10) 100 Culture V PTL 4% 53% <0.05
Goldenberg RL (23) 351 Culture Cord blood PTL 3.2% 34.7% <0.001
Gonzalez Bosquet E (87) 250 Culture V PTL 32% 65% <0.05
Donders GG (57) 759 Culture V PTL 1.2% 8.6% <0.001
Penni SC 179 PCR AF PPROM 16.8% 100% <0.001
Massaro G (88) 108 PCR V PPROM + PTL 23.3% 100% <0.001
Caroll SG (14) 45 Culture AF PTL - 27% -
Berg TG (42) 2718 Culture AF PTL 1.8% - -
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